Lipocine Q1 net loss widens on higher R&D costs

Lipocine

07/05/2026 21:57

Overview

U.S. biopharma firm's Q1 net loss widened yr/yr as R&D expenses increased

Q1 royalty revenue rose modestly from prior year

Phase 3 trial for LPCN 1154 in postpartum depression did not meet primary endpoint

Outlook

Lipocine is evaluating options for LPCN 1154, including further development or strategic transactions

Company awaits FDA feedback on breakthrough therapy and fast track applications for LPCN 1154

Lipocine continues to seek TLANDO partnerships outside the U.S., Canada, South Korea, GCC, and Brazil

Result Drivers

R&D EXPENSES - Higher research and development expenses mainly due to increased costs related to the LPCN 1154 clinical study

ADMINISTRATIVE COSTS - General and administrative expenses rose, primarily due to increased professional and consulting fees

ROYALTY REVENUE - Modest increase in royalty revenue from TLANDO sales

Company press release: ID:nPn26jLlwa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.54
Q1 Net Income
-$3.70 mln
Q1 Basic EPS
-$0.54


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lipocine Inc is $6.00, about 146.9% above its May 6 closing price of $2.43

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)